196808-45-4

• 常用中文名：Farglitazar
• 常用英文名：Farglitazar
• CAS号：196808-45-4
• 分子式：C₃₄H₃₀N₂O₅
• 分子量：546.61200
• 相关类别： 信号通路 细胞周期/DNA损伤 PPAR
• 发布时间：2017-07-19 14:43:34
• 更新时间：2024-01-10 10:14:14
• 法格列他扎尔是一种PPARγ激动剂,对2型糖尿病患者具有显著的治疗益处,如血糖控制。

名称

• 英文名: (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
• 英文别名: N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; L-Tyrosine,N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); Farglitazar; N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yI)ethyl]-L-tyrosine; (2S)-((2-benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl}-propionic acid; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID

物化性质

• 沸点: 793.7ºC at 760 mmHg
• 分子式: C₃₄H₃₀N₂O₅
• 分子量: 546.61200
• 闪点: 433.8ºC
• 精确质量: 546.21500
• PSA: 101.66000
• LogP: 6.68330
• 蒸汽压: 1.45E-26mmHg at 25°C
• 折射率: 1.639

生物活性

• 描述: 法格列他扎尔是一种PPARγ激动剂,对2型糖尿病患者具有显著的治疗益处,如血糖控制。
• 相关类别:
  信号通路 >> 细胞周期/DNA损伤 >> PPAR
  研究领域 >> 代谢疾病
• 参考文献:

  [1]. Chen L, Yang B, McNulty JA, et al. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther. 2005;312(2):718-725.

合成路线

196810-20-5 ~% 196808-45-4

文献：Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington Jr., W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A.; Kaldor, Istvan; Kliewer, Steven A.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen M.; Lenhard, James M.; Orband-Miller, Lisa A.; Miller, John F.; Mook Jr., Robert A.; Noble, Stewart A.; Oliver Jr., William; Parks, Derek J.; Plunket, Kelli D.; Szewczyk, Jerzy R.; Willson, Timothy M. Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5020 - 5036

103788-65-4 ~% 196808-45-4

文献：Collins, Jon L.; Blanchard, Steven G.; Boswell, G. Evan; Charifson, Paul S.; Cobb, Jeff E.; Henke, Brad R.; Hull-Ryde, Emily A.; Kazmierski, Wieslaw M.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen; Lenhard, James M.; Orband-Miller, Lisa A.; Gray-Nunez, Yolanda; Parks, Derek J.; Plunkett, Kelli D.; Tong, Wei-Qin Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5037 - 5054

1080-06-4 ~% 196808-45-4

文献：Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington Jr., W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A.; Kaldor, Istvan; Kliewer, Steven A.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen M.; Lenhard, James M.; Orband-Miller, Lisa A.; Miller, John F.; Mook Jr., Robert A.; Noble, Stewart A.; Oliver Jr., William; Parks, Derek J.; Plunket, Kelli D.; Szewczyk, Jerzy R.; Willson, Timothy M. Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5020 - 5036

3580-38-9 ~% 196808-45-4

文献：Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington Jr., W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A.; Kaldor, Istvan; Kliewer, Steven A.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen M.; Lenhard, James M.; Orband-Miller, Lisa A.; Miller, John F.; Mook Jr., Robert A.; Noble, Stewart A.; Oliver Jr., William; Parks, Derek J.; Plunket, Kelli D.; Szewczyk, Jerzy R.; Willson, Timothy M. Journal of Medicinal Chemistry, 1998 , vol. 41, # 25 p. 5020 - 5036